Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo [4,5-d] pyrimidine derivatives as adenosine A2A receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 3, 2010, Pages 1214-1218

  Luthra, Pratibha Mehta ^a   Mishra, Chandra Bhushan ^a   Jha, Pawan Kumar ^a   Barodia, Sandeep Kumar ^a  

^a UNIVERSITY OF DELHI   (India)

Author keywords

Adenosine; Combinatorial chemistry; GPCR; Parkinson's disease; Radioligand binding; Thiazolopyrimidines

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 7 IMINO 2 THIOXO 3,7 DIHYDRO 2H THIAZOLO [4,5 D]PYRIMIDINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; CYCLIC AMP; FURAN DERIVATIVE; ISTRADEFYLLINE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THIAZOLOPYRIMIDINE; UNCLASSIFIED DRUG; UREA DERIVATIVE; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PARKINSON DISEASE; PHARMACOPHORE; RADIOASSAY; CELL LINE; COMPARATIVE STUDY; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADENOSINE A2 RECEPTOR ANTAGONISTS; CELL LINE; HUMANS; PROTEIN BINDING; PYRIMIDINES; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 74049150476     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.11.133     Document Type: Article

References (34)

1. Jenner P. Neurology 61 (2003) S32
2. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S. Nat. Med. 10 (2004) S2
3. Olanow C.W., and Obeso J.A. Ann. Neurol. 47 (2000) S167
4. Kanda T., Shiozaki S., Shimada J., Suzuki F., and Nakamura J. Eur. J. Pharmacol. 256 (1994) 263
5. Fenu S., Pinna A., Ongini E., and Morelli M. Eur. J. Pharmacol. 321 (1997) 143
6. Kanda T., Jackson M.J., Smith L.A., Pearce R.K.B., Nakamura J., Kase H., Kuwana Y., and Jenner P. Ann. Neurol. 43 (1998) 507
7. Aoyama S., Kase H., and Borrelli E. J. Neurosci. 20 (2000) 5848
8. Svenningsson P., LeMoine C., Fisone G., and Fredholm B.B. Prog. Neurobiol. 59 (1999) 355
9. Fuxe K., Marcellino D., Genedani S., and Agnati L. Mov. Disord. 22 (2007) 1990
10. Chen J.F., Sonsalla P.K., Pedata F., Melani A., Domenici M.R., Popoli P., Geiger J., Lopes L.V., and Mendonça A. Prog. Neurobiol. 83 (2007) 310
11. Shiozaki S., Ichikawa S., Nakamura J., Kitamura S., Yamada K., and Kuwana Y. Actions Psychopharmacol. 147 (1999) 90
12. Kanda T., Jackson M.J., Smith L.A., Pearce R.K.B., Nakamura J., Kase H., Kuwana Y., and Jenner P. Exp. Neurol. 162 (2000) 321
13. Hauser R.A., and Schwarzschild M.A. Drugs Aging 22 (2005) 471
14. LeWitt P.A., Guttman M., Tetrud J.W., Tuire P.J., Mori A., Chaikin P., and Sussman N.M. Ann. Neurol. 63 (2008) 295
15. http://www.kyowa-kirin.co.jp/english/news/2009/e20090115_01.html.
16. Caulkett P.W.R., Jones G., McPartlin M., Renshaw N.D., Stewart S.K., and Wright B.J. J. Chem. Soc., Perkin Trans.1 (1995) 801
17. Baraldi P.G., Cacciari B., Spalluto G., Pineda de Villatoro M.J., Zocchi C., Dionisotti S., and Ongini E. J. Med. Chem. 39 (1996) 1164
18. Zocchi C., Ongini E., Conti A., Monopoli A., Negretti A., Baraldi P.G., and Dionisotti S.J. Pharmacol. Exp. Ther. 276 (1996) 398
19. Baraldi P.G., Cacciari B., Romagnoli R., Spalluto G., Monopoli A., Ongini E., Varani K., and Borea P.A. J. Med. Chem. 45 (2002) 115
20. Kisselgof E., Tulshian D.B., Arik L., Zhang H., and Fawzi A. Bioorg. Med. Chem. Lett. 15 (2005) 2119
21. Hirota T., Sasaki K., Tashima Y., and Nakayaama T. J. Hetrocyclic Chem. 28 (1991) 263
22. Nagamatsu T., kinoshita K., Sasaki K., Nakayama T., and Hirota T. J. Hetrocyclic Chem. 28 (1991) 513
23. Hirota T., Leno K., and Sasaki K. J. Heterocycl. Chem. 23 (1986) 1685
24. Helal C.J., Sanner M.A., Cooper C.B., Gant T., Adam M., Lucas J.C., Kang Z., Kupchinsky S., Ahlijanian M.K., Tate B., Menniti F.S., Kelly K., and Peterson M. Bioorg. Med. Chem. Lett. 14 (2004) 5521
25. Slee, D.; Lanier M.; Vong, B.G.; Chen, Y.; Zhang, X.; Lin, E.; Moorjani, M.; Castro, P.; Laria, J.C. US Patent 20, 080, 275, 064, 06 November 2008.
26. Ohlmeyer M.H.J., Swanson R.N., Dillard L., Reader J.C., Asouline G., Kobayishi R., Wigler M., and Still W.C. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 10922
27. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y.T., Lane J.R., Ijzerman A.P., and Stevens R.C. Science 322 (2008) 1211
28. 6) were treated with 100 nM of compounds (15-26), 100 nM SCH58261 and 100 nM of NECA for 24 h, 0.1 N HCl was added to release endogenous cAMP, centrifuged at 1000g for 5 min at 4 °C. cAMP concentrations were measured (P. Tijssen, 'Practice & theory of enzyme immunoassays', (1985) Amsterdam, Elsevier) in the treated cells, and the results were compared with untreated cells (representing basal level of cAMP in the cells).
29. +), 285 (M+1).
30. i values were calculated using Cheng and Prusoff formula.
31. Ongini E. Drug Dev. Res. 42 (1998) 63
32. Ongini E., Dionisotti S., Gessi S., Irenius E., and Fredholm B.B. Naunyn Schmiedebergs Arch. Pharmacol. 359 (1999) 7
33. Linden J., Thai T., Figler H., Jin X., and Robeva A.S. Mol. Pharmacol. 56 (1999) 705
34. Shimada J., Koike N., Nonaka H., Shiozaki S., Yanagawa K., Kanda T., Kobayashi S., Ichimura M., Nakamura J., Kase H., and Suzuki F. Bioorg. Med. Chem. Lett. 7 (1997) 2349